OTC Markets OTCQB - Delayed Quote USD
NUREXONE BIOLOGIC INC (NRXBF)
0.4920
+0.0063
+(1.30%)
As of April 23 at 2:59:05 PM EDT. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Yoram Drucker | Co-Founder, VP of Strategic Development & Chairman | 69.53k | -- | 1965 |
| Dr. Lior Shaltiel Ph.D. | CEO & Director | 214.16k | -- | -- |
| Mr. Eran Ovadya M.B.A. | CFO, Financial Director & Secretary | 214.58k | -- | -- |
| Mr. Gabriel Eldor | Co-Founder & Business Development Manager | -- | -- | -- |
| Dr. Shulamit Levenberg Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | 1963 |
| Dr. Daniel Offen Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Dr. Tali Kizhner | Director of Research & Development | -- | -- | -- |
| Prof. Nahshon Knoller M.D. | Head of the neurosurgery department at Shiba & Member of Scientific Advisory Board | -- | -- | -- |
| Dr. Ina Sarel Ph.D. | Head of CMC, Quality & Regulation | -- | -- | -- |
| Mr. Nirit Drori-Carmi M.Sc. | Head of Bioprocess Development | -- | -- | -- |
NUREXONE BIOLOGIC INC
1 First Canadian Place
Suite 1600 100 King Street West
Toronto, ON M5X 1G5
Canada
- Sector:
- Healthcare
- Industry: Biotechnology
Description
NurExone Biologic Inc., operates as a pharmaceutical technology company. It is developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. The company was founded in 2020 and is based in Toronto, Canada.
Corporate Governance
NUREXONE BIOLOGIC INC’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
LSB LakeShore Biopharma Co., Ltd
1.3300
0.00%
IMRN Immuron Limited
1.7205
-2.80%
BCT.TO BriaCell Therapeutics Corp.
8.47
+18.96%
DRTS Alpha Tau Medical Ltd.
2.6400
-0.38%
CLGN CollPlant Biotechnologies Ltd.
2.2100
+7.28%
PASG Passage Bio, Inc.
0.3286
-2.23%
PPBT Purple Biotech Ltd
2.7300
+1.10%
MRKR Marker Therapeutics, Inc.
1.2550
+5.46%
SCPH scPharmaceuticals Inc.
2.4950
-4.04%
SVA.TO Sernova Biotherapeutics Inc
0.2050
-6.82%